Michael Davenport1, Kathleen E Mach1, Linda M Dairiki Shortliffe1, Niaz Banaei2, Tza-Huei Wang3, Joseph C Liao1,4. 1. Department of Urology, Stanford University School of Medicine, 300 Pasteur Drive S-287, Stanford, California 94305 USA. 2. Department of Pathology, Stanford University School of Medicine, 3375 Hillview Avenue, Palo Alto, California 94304 USA. 3. Departments of Mechanical and Biomedical Engineering, Johns Hopkins University, 3400 N. Charles Street, Baltimore, Maryland 21218, USA. 4. Veterans Affairs Palo Alto Health Care System, 3801 Miranda Avenue, Palo Alto, California 94304 USA.
Abstract
Timely and accurate identification and determination of the antimicrobial susceptibility of uropathogens is central to the management of UTIs. Urine dipsticks are fast and amenable to point-of-care testing, but do not have adequate diagnostic accuracy or provide microbiological diagnosis. Urine culture with antimicrobial susceptibility testing takes 2-3 days and requires a clinical laboratory. The common use of empirical antibiotics has contributed to the rise of multidrug-resistant organisms, reducing treatment options and increasing costs. In addition to improved antimicrobial stewardship and the development of new antimicrobials, novel diagnostics are needed for timely microbial identification and determination of antimicrobial susceptibilities. New diagnostic platforms, including nucleic acid tests and mass spectrometry, have been approved for clinical use and have improved the speed and accuracy of pathogen identification from primary cultures. Optimization for direct urine testing would reduce the time to diagnosis, yet these technologies do not provide comprehensive information on antimicrobial susceptibility. Emerging technologies including biosensors, microfluidics, and other integrated platforms could improve UTI diagnosis via direct pathogen detection from urine samples, rapid antimicrobial susceptibility testing, and point-of-care testing. Successful development and implementation of these technologies has the potential to usher in an era of precision medicine to improve patient care and public health.
Timely and accurate identification and determination of the antimicrobial susceptibility of uropathogens is central to the management of pan class="Gene">UTIs. Urine dipsticks are fast and amenable to point-of-care testing, but do not have adequate diagnostic accuracy or provide microbiological diagnosis. Urine culture with antimicrobial susceptibility testing takes 2-3 days and requires a clinical laboratory. The common use of empirical antibiotics has contributed to the rise of multidrug-resistant organisms, reducing treatment options and increasing costs. In addition to improved antimicrobial stewardship and the development of new antimicrobials, novel diagnostics are needed for timely microbial identification and determination of antimicrobial susceptibilities. New diagnostic platforms, including nucleic acid tests and mass spectrometry, have been approved for clinical use and have improved the speed and accuracy of pathogen identification from primary cultures. Optimization for direct urine testing would reduce the time to diagnosis, yet these technologies do not provide comprehensive information on antimicrobial susceptibility. Emerging technologies including biosensors, microfluidics, and other integrated platforms could improve UTI diagnosis via direct pathogen detection from urine samples, rapid antimicrobial susceptibility testing, and point-of-care testing. Successful development and implementation of these technologies has the potential to usher in an era of precision medicine to improve patient care and public health.
Authors: Gennifer T Smith; Nicholas Dwork; Saara A Khan; Matthew Millet; Kiran Magar; Mehdi Javanmard; Audrey K Ellerbee Bowden Journal: Lab Chip Date: 2016-05-24 Impact factor: 6.799
Authors: Ying Pan; Geoffrey A Sonn; Mandy L Y Sin; Kathleen E Mach; Mei-Chiung Shih; Vincent Gau; Pak Kin Wong; Joseph C Liao Journal: Biosens Bioelectron Date: 2010-07-08 Impact factor: 10.618
Authors: Melissa K Deck; Erica S Anderson; Rebecca J Buckner; Georgia Colasante; Thomas E Davis; James M Coull; Benjamin Crystal; Phyllis Della Latta; Martin Fuchs; Deanna Fuller; Will Harris; Kevin Hazen; Lisa L Klimas; Daniel Lindao; Michelle C Meltzer; Margie Morgan; Janeen Shepard; Sharon Stevens; Fann Wu; Mark J Fiandaca Journal: Diagn Microbiol Infect Dis Date: 2013-12-14 Impact factor: 2.803
Authors: Walter L J M Devillé; Joris C Yzermans; Nico P van Duijn; P Dick Bezemer; Daniëlle A W M van der Windt; Lex M Bouter Journal: BMC Urol Date: 2004-06-02 Impact factor: 2.264
Authors: Hui Li; Peter Torab; Kathleen E Mach; Christine Surrette; Matthew R England; David W Craft; Neal J Thomas; Joseph C Liao; Chris Puleo; Pak Kin Wong Journal: Proc Natl Acad Sci U S A Date: 2019-05-08 Impact factor: 11.205
Authors: Matthew Dixon; Maria Stefil; Michael McDonald; Truls Erik Bjerklund-Johansen; Kurt Naber; Florian Wagenlehner; Vladimir Mouraviev Journal: World J Urol Date: 2019-04-03 Impact factor: 4.226
Authors: Travis K Price; Evann E Hilt; Tanaka J Dune; Elizabeth R Mueller; Alan J Wolfe; Linda Brubaker Journal: Int Urogynecol J Date: 2017-12-26 Impact factor: 2.894